GTS Securities’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-543,700
Closed -$28.1M 1602
2024
Q3
$28.1M Sell
543,700
-22,000
-4% -$1.03M 0.06% 190
2024
Q2
$23.5M Buy
565,700
+150,800
+36% +$6.75M 0.05% 218
2024
Q1
$22.5M Buy
414,900
+71,200
+21% +$3.63M 0.04% 235
2023
Q4
$17.6M Buy
343,700
+26,400
+8% +$1.39M 0.03% 377
2023
Q3
$18.4M Buy
+317,300
New +$19.4M 0.03% 363

Other funds holding BMY

GTS Securities's BMY Position: Q1 2026 in Review

GTS Securities reduced its Bristol-Myers Squibb (BMY) stake by 68% in Q1 2026, selling an estimated $767K and leaving 6,135 shares worth $372K. The position accounts for 0.01% of the portfolio, ranked #954.

GTS Securities first reported a position in BMY in Q2 2023 and has held it in 12 quarters since. The position peaked at $13.5M in Q4 2023. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • GTS Securities held 6,135 shares of Bristol-Myers Squibb worth $372K as of Q1 2026.
  • GTS Securities sold 13,152 Bristol-Myers Squibb shares in Q1 2026, an estimated $767K.
  • Bristol-Myers Squibb made up 0.01% of GTS Securities's portfolio in Q1 2026, its #954 holding.
  • GTS Securities first reported a position in Bristol-Myers Squibb in Q2 2023 and has held it in 12 quarters since.
  • GTS Securities's Bristol-Myers Squibb position peaked at $13.5M in Q4 2023.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.